Effects of levonorgestrel-releasing intrauterine system for dysmenorrhea patients with adenomyosis
-
摘要: 目的 探讨左炔诺孕酮宫内释放系统治疗对子宫腺肌病痛经患者疼痛程度、血清糖类抗原125(CA125)及性激素的影响。 方法 选取子宫腺肌病痛经患者118例,按照随机数字表法分为对照组和观察组,每组59例。对照组采用孕三烯酮进行治疗,观察组采用左炔诺孕酮宫内释放系统进行治疗。分析2组患者的痛经疼痛程度、子宫内膜厚度及子宫体积、血清CA125、雌二醇(E2)、卵泡刺激素(FSH)及黄体生成素(LH)指标变化情况。 结果 治疗后,观察组疼痛程度显著低于对照组(P<0.05); 观察组子宫内膜厚度及子宫体积显著小于对照组(P<0.05); 观察血清CA125水平显著低于对照组,且E2水平显著高于对照组(P<0.05); 2组患者FSH与LH水平比较,差异无统计学意义(P>0.05)。 结论 采用左炔诺孕酮宫内释放系统对围绝经期子宫腺肌病痛经患者进行治疗,能够有效缓解疼痛,缩小患者子宫内膜厚度及子宫体积,调节性激素水平,安全性较高。
-
关键词:
- 左炔诺孕酮宫内释放系统 /
- 子宫腺肌病 /
- 痛经 /
- 糖类抗原125 /
- 性激素
Abstract: Objective To explore the effects of levonorgestrel-releasing intrauterine system on pain, serum carbohydrate antigen 125(CA125)and sex hormones in adenomyosis patients with dysmenorrhea. Method A total of 118 adenomyosis patients with dysmenorrhea were selected and divided into control group and observation group according to random number table method, with 59 cases in each group. The control group was treated with progesterone, while the observation group was treated with levonorgestrel-releasing intrauterine system. The changes in the degree of dysmenorrhea pain, endometrial thickness and uterine volume, serum CA125, estradiol(E2), follicle-stimulating hormone(FSH)and luteining hormone(LH)were compared and analyzed in the two groups. Results After treatment, the degree of dysmenorrhea in the observation group was significantly lower than that in the control group(P<0.05), the endometrial thickness and uterine volume in the observation group were significantly smaller than those in the control group(P<0.05), the level of serum CA125 in the observation group was significantly lower than that in the control group, and the level of E2 was significantly higher than that in the control group(P<0.05). There were no significant differences in FSH and LH levels between the two groups(P>0.05). Conclusion Levonorgestrel-releasing intrauterine system for treatment of dysmenorrhea patients with perimenopausal adenomyosis can effectively relieve the pain, improve the intrauterine membrane thickness and uterine volume, and regulate the level of sex hormones, and it has higher safety. -
-
李妞妞, 郭广玲, 王铁延. 子宫内膜异位症与免疫炎症、氧化应激及血管生成的相关性研究[J]. 标记免疫分析与临床, 2018, 25(4):468-471. 唐秋林, 陈桂清, 罗爽. 达菲林联合高强度聚焦超声治疗子宫腺肌病100例临床观察[J]. 中国药业, 2018, 27(10):81-83. 常梦茹, 卢美松, 张丹丹. 磁共振引导高强度聚焦超声术治疗子宫腺肌病的临床研究进展[J]. 中国计划生育和妇产科, 2018, 10(9):6-9. 张彩玩, 邓森灵. 子宫腺肌病患者应用腹腔镜子宫楔形切除术并术后阴道置放左炔诺孕酮宫内缓释系统治疗效果观察[J]. 中国性科学, 2018, 27(4):106-108. 中华医学会妇产科学分会子宫内膜异位症协作组. 子宫内膜异位症的诊治指南[J]. 中华妇产科杂志, 2015, 2(3):161-169. 杜成超, 周洪贵. 核磁共振成像在高强度聚焦超声治疗子宫腺肌病中的价值[J]. 中国计划生育和妇产科, 2018, 10(4):30-34. 黄伟媚, 黄卡立. 子宫腺肌病合并不孕接受达菲林超长方案超促排卵后行IVF-ET治疗效果回顾性分析[J]. 中国性科学, 2018, 27(7):82-85. 古子娟, 卢如玲, 袁烁, 等. 散结镇痛胶囊联合曼月乐治疗子宫腺肌病的Meta分析[J]. 中国医药导报, 2018, 15(6):88-93. 马鑫, 梁丽, 刘福民. PEDF、VEGF在子宫腺肌病组织中的表达及临床意义的研究[J]. 徐州医科大学学报, 2018, 38(8):524-528. 吴佳, 周秋萍, 郑虹, 等. 左炔诺孕酮宫内缓释系统治疗子宫腺肌症的临床观察[J]. 实用临床医药杂志, 2011, 15(17):174-175. 周琴, 徐晓燕, 蒋婧婧, 等. 经阴道三维彩色多普勒超声在子宫腺肌病诊断及治疗中的应用价值[J]. 现代妇产科进展, 2018, 27(3):215-217. 魏华莉, 牛秀敏, 王红霞. 注射用醋酸亮丙瑞林微球联合左炔诺孕酮宫内释放系统治疗子宫腺肌病患者的临床疗效[J]. 医学临床研究, 2019, 36(9):1736-1738 , 1741.
郭春凤, 黄修菊, 张琴悦, 等. 腹腔镜病灶剔除术联合孕三烯酮治疗子宫腺肌病疗效分析[J]. 中国妇幼保健, 2018, 33(18):4297-4299. 郑桂珍. 左炔诺孕酮宫内释放系统治疗子宫腺肌症的效果观察[J]. 深圳中西医结合杂志, 2017, 27(24):99-100. 李爱萍. 促性腺激素释放激素激动剂及左炔诺孕酮宫内缓释系统辅助治疗子宫腺肌病的效果及对痛经程度及生存质量的影响[J]. 中国妇幼保健, 2018, 33(7):1478-1480. 陈志芳. 左炔诺孕酮宫内释放系统联合桂枝茯苓胶囊治疗子宫腺肌症的临床效果[J]. 河南医学研究, 2018, 27(16):2969-2970. 王文莉, 张颖, 郭银树, 等. GnRH-a联合左炔诺孕酮宫内缓释系统治疗子宫腺肌病的临床疗效研究[J]. 医学综述, 2018, 24(13):2689-2692. 罗英媚, 李庆, 麦燕, 等. 左炔诺孕酮宫内节育系统放置前给予戈舍瑞林治疗子宫腺肌病合并重度痛经的临床观察[J]. 中国药房, 2017, 28(26):3671-3674. 涂皎, 牟萌, 古衡芳, 等. 左炔诺孕酮宫内缓释系统不同应用方法治疗子宫腺肌病疗效观察[J]. 新乡医学院学报, 2019, 36(1):33-37.
计量
- 文章访问数: 298
- HTML全文浏览量: 45
- PDF下载量: 7
下载:
苏公网安备 32100302010246号
